Hypera Pharma Switches to Rimini Street Support for Its SAP Applications
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Hypera Pharma, Brazil’s largest pharmaceutical company, has switched from SAP to Rimini Street Support for its highly customized SAP ECC 6.0 applications, Microsoft SQL Server Database and SAP BusinessObjects software. The company also switched from SAP’s Solution Manager to Rimini Street Watch for SAP, ensuring seamless monitoring for its SAP systems. By switching to Rimini Street Support, Hypera Pharma was able to leverage its significant support savings to fund the company’s business transformation priorities, including expanding the corporate pharmaceutical brand and funding cutting-edge pharmaceutical research and development (R&D) with Hynova, the company’s modern research center in Brazil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201020005451/en/
Hypera Pharma Switches to Rimini Street Support for its SAP Applications (Photo: Business Wire)
Procurement Drives Innovation by Partnering with IT And Business Leaders
Based in São Paulo, Hypera Pharma produces popular medicine brands used by over 200 million Brazilians, along with vitamins, nutritional supplements and dermo cosmetics. At the end of 2017, the company announced a new corporate brand with an exclusive focus on the pharmaceutical sector, a competitive industry that demands high investments in innovation and R&D, along with increasing capacity to launch new products and medicines to its consumers more often. This new business direction sparked Hypera Pharma’s leaders to reinvent its operations, realign business priorities and seek out initiatives to drive cost optimization.
The decision to move to Rimini Street Support was spearheaded by Hypera Pharma’s heads of procurement and IT, who were tasked with optimizing resources and saw the opportunity to reduce the spending for the company’s high SAP maintenance and support costs and at the same time improve support service. They worked closely to create a business case to demonstrate to the company’s CEO that switching to third-party support would bring security, operational efficiency and savings. The company’s heads of procurement and IT determined that Hypera Pharma should not be locked into the vendor’s time-bound upgrade path to S/4HANA as it did not make sense for the business in the short term. They found little value and no ROI in making this highly disruptive move when their current customized ERP system perfectly met their business needs.
“Procurement leaders should feel empowered to bring ideas to company leaders on how their organization can be more strategic and align with business priorities. They can influence decision-makers on how IT initiatives, such as adopting third-party support, adds value and frees up resources for other important projects and innovation,” said Humberto Guimaraes, head of procurement, Hypera Pharma. “Switching to Rimini Street Support is part of a new mindset that has enabled the company to be more relevant in the pharmaceutical industry. With our support savings, we can increase investments across the business, including product R&D, digitalization, process automation and new ERP applications that modernize logistics operations and allow product traceability.”
Ultra-Responsive Support with Industry-Leading SLAs
Hypera Pharma, along with all Rimini Street clients, benefits from the Company’s flexible, premium-level enterprise software support model, including its industry-leading Service Level Agreement (SLA) of 10-minute response times for all critical Priority 1 cases. Clients are also assigned a Primary Support Engineer, backed by a team of functional and technical experts with an average of 15 years’ experience in the client’s specific enterprise software system. Hypera Pharma was using some components of SAP Solution Manager, but working with Rimini Street’s Proactive Support Services team, the company instead implemented Rimini Street Watch for SAP. The solution combines proactive diagnostics and web-based dashboards to help Hypera Pharma identify and mitigate issues before they become critical.
“Maintaining our ERP support with SAP meant staying in the comfort zone. Rimini Street showed that the change to third-party support is worthwhile. Now we have reduced our SAP maintenance and support costs, allowing those resources to be directed towards our current business goals. We no longer worry about our ERP support since switching to Rimini Street,” continued Guimaraes.
“Modern companies in the digital era like Hypera Pharma, who want to maintain a leadership position in the market, need to optimize their IT costs and find resources to invest in innovation and business transformation,” said Edenize Maron, general manager, Latin America, Rimini Street. “The company’s heads of procurement and IT spearheaded the change to third-party support to generate cost savings that contributed to the organization’s strategic business goals, including modernizing logistics and accelerating R&D to bring products to market quicker. This demonstrates how key it is that all company leaders participate in supporting growth and innovation.”
About Rimini Street, Inc.
Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 3,500 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.
Forward-Looking Statements
Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the duration of and economic, operational and financial impacts on Rimini Street’s business of the COVID-19 pandemic, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt Rimini Street’s business or that of its current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; Rimini Street’s need and ability to raise additional equity or debt financing on favorable terms and Rimini Street’s ability to generate cash flows from operations to help fund increased investment in Rimini Street’s growth initiatives; the sufficiency of Rimini Street’s cash and cash equivalents to meet its liquidity requirements; the terms and impact of Rimini Street’s outstanding 13.00% Series A Preferred Stock; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of Rimini Street’s recently introduced products and services, including its Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services Rimini Street expects to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those risks discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 5, 2020 and as updated from time to time by other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.
© 2020 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005451/en/
Contact information
Michelle McGlocklin
Rimini Street, Inc.
+1 925 523-8414
mmcglocklin@riministreet.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 02:00:00 EEST | Press release
The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster than the global economy, generating significant commercial opportunities as long as the mounting challenges of climate change, labour shortages and infrastructure gaps are addressed. Inbound and outbound trips increasing fast Asia is on track to become the world’s fastest-growing tourism economy, with the direct travel and tourism GDP contribution expected to exceed 7% across the region by 2034. Notably, India and China
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 22:00:00 EEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 15:59:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 15:05:00 EEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
Tinnitus Research: Novel Compound AC102 Makes Constant Ear Noise Disappear in Preclinical Model3.7.2025 13:02:00 EEST | Press release
The novel compound AC102 almost completely reversed tinnitus in a preclinical model after a single dose. At the same time, the damaged connections between the auditory nerve and inner ear sensory cells were restored. These findings were recently published in the prestigious International Journal of Molecular Sciences in a joint study conducted by Erlangen University Hospital and Berlin-based drug developer AudioCure. As there is currently no causal treatment for tinnitus, there is a high medical need. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702168211/en/ In 10-20% of tinnitus cases, the noise in the ear is so severe that it significantly impairs the quality of life of those affected. (Source: AI-generated) In the current study, AC102 was administered to the middle ear of one experimental group after acoustic trauma, while a second group received a placebo. Although both groups initially showed signs of tinnitus, th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom